All In Biotech

Drug Trial Radar · NCT04492241

Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution for the Treatment of Motoric Cognitive Risk Syndrome

Evaluation of Efficacy and Safety of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution for the Treatment of Motoric Cognitive Risk Syndrome: A Multi-centre, Randomised, Double Blind and Placebo-controlled Study

Last checked: Nov 20, 2026Latest source record: Dec 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

800

Planned (sponsor's estimate)

Start

Jul 5, 2021

Primary completion

Dec 31, 2023

Study completion Dec 31, 2024

Sponsor

Lead sponsor
Beijing Tiantan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Beijing Stroke Association
First posted
Jul 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 60 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-centre, randomised, double blind, placebo controlled study on participants with Motoric Cognitive Risk Syndrome to evaluate the efficacy and safety of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution.

Conditions

  • Motoric Cognitive Risk Syndrome
  • Mild Cognitive Impairment
  • Aging
  • Locomotive Syndrome

Interventions

  • Ginkgo Leaf Extract and Armillariella Mellea Powder Oral SolutionDrug

    TID for 6 month after enrolment Glass oral bottle, 10 ml/bottle. Study Arm Component: Ginkgo Leaf Extract and Armillariella Mellea Powder, konjac (sweetener), purified water.

  • Simulation of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral SolutionDrug

    TID for 6 month after enrolment Glass oral bottle, 10 ml/bottle. Placebo Arm Component: Caramel color (food color), konjac (sweetener), sucrose octaacetate (food additive), sodium benzoate (food additive), purified water.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change of ADAS-CogTime frame: 6 month after enrolment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tiantan Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.